An anti-helicobacter pylori composition and a method for preparing the same

Abstract

The application relates to the technical field of medicine, and particularly discloses an anti-Helicobacter pylori composition and a preparation method thereof. The anti-Helicobacter pylori composition comprises the following components in parts by weight: 0.5-2 parts of isomaltooligosaccharide, 1-2 parts of galactooligosaccharide, 3-5 parts of sea buckthorn powder, 0.5-1.5 parts of sorbitol, 0.1-0.5 parts of L-glutamine and 0.3-0.5 parts of Lactobacillus reuteri composite microcapsules. The preparation method comprises the following steps: uniformly mixing the isomaltooligosaccharide, the galactooligosaccharide and the sorbitol, then uniformly mixing the sea buckthorn powder, finally uniformly mixing the Lactobacillus reuteri composite microcapsules, and then performing separate packaging and storage to obtain the anti-Helicobacter pylori composition. The anti-Helicobacter pylori composition can more effectively combine with Helicobacter pylori in a severe change of a gastric acid environment, and then can exert a remarkable and excellent Helicobacter pylori removal effect.

Description

TECHNICAL FIELD

[0001] The present application relates to the medical technical field, more particularly, it relates to an anti-helicobacter pylori composition and a preparation method thereof. BACKGROUND

[0002] Helicobacter pylori is a microaerophilic gram-negative bacillus, mainly parasitizing in the human antrum and pylorus, and its pathogenic effect mainly manifests as the bacterial colonization on the gastric mucosa, invasion into the host's immune defense system, direct action of the toxin, and induced inflammatory and immune responses.

[0003] Gastritis is a general term for acute and chronic inflammation of the gastric mucosa, which has a close relationship with helicobacter pylori. Helicobacter pylori can produce various enzymes and toxins, which can destroy the protective barrier of the gastric mucosa and trigger an inflammatory response, thereby causing gastritis. When infected with helicobacter pylori, the bacteria can infect the gastric mucosa and form inflammation. If the gastric mucosa is chronically stimulated by inflammation, intestinalization and atrophy may occur.

[0004] For gastritis caused by helicobacter pylori, the existing technology includes western medicine and traditional Chinese medicine therapy. Western medicine mainly uses triple and quadruple antibiotics for centralized administration, which not only kills helicobacter pylori but also kills the beneficial bacteria in the human intestinal tract, causing a strong rejection reaction in the human body, and causing harm to the enemy and self-damage. It takes 1-2 months to recover to normal. The traditional Chinese medicine therapy has a slow effect and a low eradication rate of helicobacter pylori.

[0005] In order to reduce the side effects of antibiotics, reduce the risk of drug resistance, and obtain a rapid and high helicobacter pylori eradication effect, the use of Lactobacillus reuteri and helicobacter pylori physical copolymerization provides a new choice for the elimination of helicobacter pylori. Research has found that a specific model of Lactobacillus reuteri can combine with helicobacter pylori through surface adhesion molecules to form a polymer, making it lose activity and be excreted with the digestive tract. This surrounding and combining method of helicobacter pylori can effectively prevent its colonization on the gastrointestinal mucosa and inhibit the occurrence of infection reactions, rather than killing it, but using bacteria to control bacteria to dilute, expel and neutralize it. Moreover, the specific model of Lactobacillus reuteri can also reduce the gastric load of helicobacter pylori infected population, reduce the adverse reactions of antibiotic treatment, improve the gastrointestinal symptoms, and regulate the composition of intestinal flora. Therefore, the use of Lactobacillus reuteri not only has a better helicobacter pylori elimination effect, but also is more beneficial to human health.

[0006] Regarding the aforementioned technologies, the inventors believe that gastritis can cause abnormal gastric acid secretion in patients, and the treatment of gastritis caused by Helicobacter pylori can also cause drastic changes in the gastric acid environment. This acidic change makes it difficult for Lactobacillus reuteri and Helicobacter pylori to combine and form a stable polymer, thereby affecting the eradication effect of Helicobacter pylori. Therefore, there is an urgent need to propose a solution to address the above-mentioned technical problems. Summary of the Invention

[0007] In order to enable Lactobacillus reuteri to bind more effectively to Helicobacter pylori in practical applications and thereby improve the eradication effect of Helicobacter pylori, this application provides an anti-Helicobacter pylori composition and its preparation method.

[0008] In a first aspect, this application provides an anti-Helicobacter pylori composition, which adopts the following technical solution:

[0009] An anti-Helicobacter pylori composition comprising the following components in parts by weight:

[0010] 0.5-2 parts of isomaltooligosaccharide;

[0011] 1-2 parts of galactooligosaccharides;

[0012] 3-5 parts sea buckthorn powder;

[0013] Sorbitol 0.5-1.5 parts;

[0014] L-glutamine 0.1-0.5 parts;

[0015] 0.3-0.5 parts of Lactobacillus reuteri complex microcapsules;

[0016] The Lactobacillus reuteri complex microcapsules were prepared through the following steps:

[0017] S1. Chitosan was dissolved in citric acid solution, stirred and allowed to stand, then acetone was added to precipitate the mixture. After washing and drying, chitosan-citric acid complex was obtained. Simultaneously, sodium alginate and gelatin were mixed and dissolved in deionized water to obtain a mixed sol.

[0018] S2. Take calcium citrate and mix it with the chitosan-citric acid complex and mixed sol from step S1, then add Lactobacillus reuteri raw material to disperse it, and obtain a mixed solution;

[0019] S3. The mixture obtained in step S2 is added to a calcium chloride solution for solidification to obtain solidified gel beads. After rinsing with sterile water, the mixture is freeze-dried to obtain Lactobacillus reuteri composite microcapsules.

[0020] By adopting the above technical solution, in the preparation of Lactobacillus reuteri composite microcapsules, in step S1, citric acid dissolves chitosan through protonation and induces chitosan and citric acid to form a physical cross-linking network through the dehydration effect of acetone, thus obtaining a chitosan-citric acid complex; hemin gelatin provides thermally reversible gel properties, and sodium alginate provides reaction sites for subsequent calcium ion cross-linking through carboxyl groups. The two are mixed and dissolved in deionized water to obtain a mixed sol as the main raw material for the microcapsule wall; in step S2, calcium citrate, chitosan-citric acid complex... The compound and the mixed sol form a stable mixed matrix. After mixing with Lactobacillus reuteri raw material, a mixed solution is obtained. The protonated amino groups of the chitosan-citric acid complex and the carboxyl groups of sodium alginate form a polyelectrolyte network, which can enhance the density of the microcapsule wall and effectively protect the bacteria from mechanical shear damage. The chitosan-citric acid complex enhances acid resistance, and the doping of calcium citrate ensures the controllable morphology of the microcapsules. In step S3, Lactobacillus reuteri composite microcapsules are obtained by calcium chloride curing and freeze drying. When the aforementioned *Lactobacillus reuteri* complex microcapsules are used in an anti-Helicobacter pylori composition, upon entering the human stomach, the calcium citrate in the microcapsule wall preferentially dissolves due to the influence of gastric acid. This creates pits of varying sizes on the microcapsule surface. Over time, the microcapsule wall gradually dissolves, and these pits penetrate the microcapsule wall in a multi-tiered manner, exposing *Lactobacillus reuteri* and allowing it to polymerize with *Helicobacter pylori*. During this process, the chitosan-citric acid complex in the capsule wall provides a strong load. Thus, through the tiered release and action of *Lactobacillus reuteri*, the overall impact of drastic changes in the gastric acid environment on *Lactobacillus reuteri* can be significantly reduced. This ensures the long-lasting effect of *Lactobacillus reuteri* during application and allows for more effective binding to *Helicobacter pylori*, resulting in a significant *Helicobacter pylori* eradication effect and a high-quality anti-Helicobacter pylori composition.

[0021] Preferably, in step S1 of preparing the Lactobacillus reuteri composite microcapsules, the ratio of chitosan to citric acid solution is 1g:(60-80)mL, and the concentration of citric acid solution is 1-3%.

[0022] By adopting the above technical solution, a citric acid solution concentration of 1-3% can provide sufficient H⁺ concentration to ensure the chitosan dissolution rate and avoid molecular chain breakage caused by excessive acidification. Controlling the ratio of chitosan to citric acid solution to 1g:(60-80)mL can yield a chitosan-citric acid complex with excellent stability and good processing performance. Furthermore, it exhibits better binding with the mixed sol in subsequent applications, thus achieving better corresponding effects and facilitating the production of high-quality Lactobacillus reuteri composite microcapsules.

[0023] Preferably, in step S1 of preparing the Lactobacillus reuteri complex microcapsules, the ratio of sodium alginate, gelatin and deionized water is (2.5-3.5) g: 1 g: 200 mL.

[0024] By adopting the above technical solution, the mixed sol obtained by mixing sodium alginate, gelatin and deionized water in the above proportion has moderate viscosity and rheological properties. After being mixed with calcium citrate and chitosan-citric acid, it can not only effectively encapsulate Lactobacillus reuteri, but also obtain microcapsule walls with high cross-linking density and uniform and stable structure, thereby ensuring that the obtained Lactobacillus reuteri composite microcapsules can exert excellent effects after application.

[0025] Preferably, in step S2 of the preparation of the Lactobacillus reuteri complex microcapsules, the weight ratio of calcium citrate, chitosan-citric acid complex and mixed sol is 1:(10-25):(70-90).

[0026] By adopting the above technical solution, the fluidity of the above-mentioned proportions of calcium citrate, chitosan-citric acid complex and mixed sol is moderate, and it can be stably shaped in subsequent operations after being mixed with Lactobacillus reuteri raw material. At the same time, the synergistic effect of calcium citrate, chitosan-citric acid complex and mixed sol in the application process is better, which makes the Lactobacillus reuteri composite microcapsules more adaptable to the drastic changes in the acid environment of the human stomach after application, and the resulting Helicobacter pylori eradication effect is also better.

[0027] Preferably, the particle size of the Lactobacillus reuteri composite microcapsules is 150-200 μm.

[0028] By adopting the above technical solution, if the particle size is lower than the above range, the Lactobacillus reuteri composite microcapsules are prone to early disintegration; if the particle size is higher than the above range, the Lactobacillus reuteri composite microcapsules will settle rapidly and have a shorter retention time in the stomach; while the Lactobacillus reuteri composite microcapsules with the above particle size range can overcome the above application defects, are more suitable for the human stomach and exert better effects.

[0029] Preferably, the amount of Lactobacillus reuteri in the anti-Helicobacter pylori composition is 1 billion to 30 billion CFU / g.

[0030] By adopting the above technical solution, the raw material cost can be controlled by the load limit of the microcapsule wall material, avoiding the risk of reduced encapsulation efficiency or wall material rupture caused by excessive bacteria, thus enabling the Lactobacillus reuteri composite microcapsules to achieve better application results during application; at the same time, different amounts of Lactobacillus reuteri anti-Helicobacter pylori compositions can be selected according to the degree of Helicobacter pylori infection, resulting in better overall applicability.

[0031] Preferably, in step S2 of the preparation of the Lactobacillus reuteri composite microcapsules, attapulgite clay with a mass ratio of 1-5% is also added to the mixture.

[0032] By adopting the above technical solution, the porous structure of attapulgite provides a physical framework for the microcapsule wall, further improving the temperature resistance of the *Lactobacillus reuteri* composite microcapsules when they exert their effects in the human stomach. Furthermore, attapulgite can synergistically enhance the stability of the polymers formed by *Lactobacillus reuteri* and *Helicobacter pylori*, and is more conducive to the elimination and expulsion of *Helicobacter pylori*, thus significantly improving the efficacy of the *Lactobacillus reuteri* composite microcapsules under drastic changes in the acidic environment of the stomach. Simultaneously, the use of attapulgite reduces the proportion of other raw materials in the microcapsule wall, improving the efficacy of the *Lactobacillus reuteri* composite microcapsules while reducing their cost, thereby enhancing their economic viability.

[0033] Preferably, the particle size of the attapulgite clay is 30-50 μm.

[0034] By adopting the above technical solution, the attapulgite of the above specifications can reduce the dimensional deviation during the molding of Lactobacillus reuteri composite microcapsules, exhibit excellent dispersion uniformity within the microcapsule wall, and stably combine with other raw materials within the microcapsule wall, thereby exerting excellent corresponding effects. This results in a significantly improved Helicobacter pylori eradication effect achieved by attapulgite in the application of Lactobacillus reuteri composite microcapsules.

[0035] Secondly, this application provides a method for preparing an anti-Helicobacter pylori composition, using the following technical solution:

[0036] A method for preparing an anti-Helicobacter pylori composition includes the following steps:

[0037] (1) Prepare raw materials containing isomaltooligosaccharide, galactooligosaccharide, sea buckthorn powder, sorbitol, L-glutamine and Lactobacillus reuteri complex microcapsules according to the formula;

[0038] (2) After mixing isomaltooligosaccharide, galactooligosaccharide and sorbitol in step (1) evenly, add sea buckthorn powder and mix evenly. Finally, add Lactobacillus reuteri complex microcapsules and L-glutamine and mix evenly. Then, package and store to obtain the anti-Helicobacter pylori composition.

[0039] By adopting the above technical solution, the anti-Helicobacter pylori composition can be obtained after the raw materials are mixed evenly. This anti-Helicobacter pylori composition can be taken directly or used as an additive in instant food, and its overall applicability is good.

[0040] In summary, this application has the following beneficial effects:

[0041] This application uses calcium citrate, chitosan-citric acid complex, and mixed sol as raw materials for the preparation of microcapsule walls to form microcapsule encapsulation of Lactobacillus reuteri raw materials, thereby obtaining Lactobacillus reuteri composite microcapsules. This can significantly reduce the overall impact of drastic changes in the gastric acid environment on Lactobacillus reuteri, enabling Lactobacillus reuteri to bind to Helicobacter pylori more effectively, thus bringing about a significant Helicobacter pylori eradication effect, and finally obtaining a high-quality anti-Helicobacter pylori composition. Detailed Implementation

[0042] The present application will be further described in detail below with reference to preparation examples, embodiments and comparative examples.

[0043] Unless otherwise specified, all raw materials used in the preparation examples, embodiments and comparative examples of this application are commercially available.

[0044] Sea buckthorn powder was purchased from Xi'an Quan'ao Biotechnology Co., Ltd., with a specification of 10:1 and a mesh size of 80 mesh.

[0045] Lactobacillus reuteri was purchased from Novozymes, France, as DSM 17648.

[0046] Preparation examples of raw materials and / or intermediates

[0047] Preparation Example 1

[0048] A Lactobacillus reuteri complex microcapsule was prepared by the following steps:

[0049] S1. Chitosan was dissolved in citric acid solution, stirred and allowed to stand for 24 hours, then acetone was added to precipitate the mixture. After washing and drying with deionized water, chitosan-citric acid complex was obtained. Simultaneously, sodium alginate and gelatin were mixed and dissolved in deionized water at 50°C to obtain a mixed sol.

[0050] S2. Take calcium citrate and mix it with the chitosan-citric acid complex and mixed sol from step S1, then add Lactobacillus reuteri raw material to disperse it, and obtain a mixed solution;

[0051] S3. The mixture obtained in step S2 is added dropwise into a 2.5% calcium chloride solution and cured for 20 minutes to obtain cured gel beads. Then, it is rinsed with sterile water and freeze-dried at -40℃ for 24 hours to obtain Lactobacillus reuteri composite microcapsules.

[0052] Note: In preparation step S1 above, the ratio of chitosan to citric acid solution is 1g:70mL, and the concentration of citric acid solution is 2%; the ratio of sodium alginate, gelatin, and deionized water is 3g:1g:200mL. In preparation step S2, the weight ratio of calcium citrate, chitosan-citric acid complex, and mixed sol is 1:17.5:80. The particle size of the Lactobacillus reuteri composite microcapsules is 175μm.

[0053] Preparation Example 2

[0054] A Lactobacillus reuteri complex microcapsule differs from Preparation Example 1 in that, in preparation step S1, the ratio of chitosan to citric acid solution is 1g:60mL, and the concentration of citric acid solution is 3%.

[0055] Preparation Example 3

[0056] A Lactobacillus reuteri complex microcapsule differs from Preparation Example 1 in that, in preparation step S1, the ratio of chitosan to citric acid solution is 1 g: 80 mL, and the concentration of citric acid solution is 1%.

[0057] Preparation Example 4

[0058] A Lactobacillus reuteri complex microcapsule differs from Preparation Example 1 in that, in preparation step S1, the ratio of sodium alginate, gelatin, and deionized water is 2.5 g: 1 g: 200 mL.

[0059] Preparation Example 5

[0060] A Lactobacillus reuteri complex microcapsule differs from Preparation Example 1 in that, in preparation step S1, the ratio of sodium alginate, gelatin, and deionized water is 3.5 g: 1 g: 200 mL.

[0061] Preparation Example 6

[0062] A Lactobacillus reuteri complex microcapsule differs from Preparation Example 1 in that, in preparation step S2, the weight ratio of calcium citrate, chitosan-citric acid complex, and mixed sol is 1:10:70.

[0063] Preparation Example 7

[0064] A Lactobacillus reuteri complex microcapsule differs from Preparation Example 1 in that, in preparation step S2, the weight ratio of calcium citrate, chitosan-citric acid complex, and mixed sol is 1:25:90.

[0065] Preparation Example 8

[0066] A Lactobacillus reuteri composite microcapsule, which differs from Preparation Example 1 in that the Lactobacillus reuteri composite microcapsule has a particle size of 150 μm.

[0067] Preparation Example 9

[0068] A Lactobacillus reuteri composite microcapsule, which differs from Preparation Example 1 in that the Lactobacillus reuteri composite microcapsule has a particle size of 200 μm.

[0069] Preparation Example 10

[0070] A Lactobacillus reuteri composite microcapsule differs from Preparation Example 1 in that, in preparation step S2, 3% by mass of attapulgite clay with a particle size of 40 μm is added to the mixture.

[0071] Preparation Example 11

[0072] A Lactobacillus reuteri composite microcapsule differs from Preparation Example 1 in that, in preparation step S2, 1% by mass of attapulgite clay with a particle size of 30 μm is added to the mixture.

[0073] Preparation Example 12

[0074] A Lactobacillus reuteri composite microcapsule differs from Preparation Example 1 in that, in preparation step S2, 5% by mass of attapulgite clay with a particle size of 50 μm is added to the mixture.

[0075] Preparation Example 13

[0076] A Lactobacillus reuteri complex microcapsule, which differs from Preparation Example 1 in that calcium citrate is not used in the mixture in preparation step S2.

[0077] Preparation Example 14

[0078] A Lactobacillus reuteri complex microcapsule, which differs from Preparation Example 1 in that, in preparation step S2, the chitosan-citric acid complex is not used in the mixture.

[0079] Preparation Example 15

[0080] A Lactobacillus reuteri complex microcapsule, which differs from Preparation Example 1 in that, in Preparation Step S2, calcium citrate and chitosan-citric acid complex were not used in the mixture.

[0081] Example

[0082] Example 1

[0083] An anti-Helicobacter pylori composition, the raw materials used in its preparation and their corresponding weight parts are shown in Table 1, and it is prepared by the following steps:

[0084] (1) Prepare raw materials containing isomaltooligosaccharide, galactooligosaccharide, sea buckthorn powder, sorbitol, L-glutamine and Lactobacillus reuteri complex microcapsules according to the formula;

[0085] (2) After mixing isomaltooligosaccharide, galactooligosaccharide and sorbitol in step (1) evenly, add sea buckthorn powder and mix evenly. Finally, add Lactobacillus reuteri complex microcapsules and L-glutamine and mix evenly. Then, package and store to obtain the anti-Helicobacter pylori composition.

[0086] Note: In the above operation, the Lactobacillus reuteri complex microcapsules were obtained from Preparation Example 1, and the amount of Lactobacillus reuteri in the obtained anti-Helicobacter pylori composition can be 1 billion to 30 billion CFU / g, and in this example it is 20 billion CFU / g.

[0087] Example 2-3

[0088] An anti-Helicobacter pylori composition differs from Example 1 in that the raw materials used in its preparation and their corresponding weight parts are shown in Table 1.

[0089] Table 1. Raw materials used in the preparation of Examples 1-3 and their corresponding weight parts (parts / kg)

[0090] Raw materials Example 1 Example 2 Example 3 Isomaltooligosaccharide 1.25 0.5 2 Galactooligosaccharide 1.5 2 1 Sea buckthorn powder 4 3 5 Sorbitol 1 1.5 0.5 L-glutamine 0.3 0.5 0.1 Lactobacillus reuteri complex microcapsule 0.5 0.3 0.4

[0091] Example 4

[0092] An anti-Helicobacter pylori composition, which differs from Example 1 in that the Lactobacillus reuteri complex microcapsules are obtained from Preparation Example 2.

[0093] Example 5

[0094] An anti-Helicobacter pylori composition, which differs from Example 1 in that the Lactobacillus reuteri complex microcapsules are obtained from Preparation Example 3.

[0095] Example 6

[0096] An anti-Helicobacter pylori composition, which differs from Example 1 in that the Lactobacillus reuteri complex microcapsules were obtained from Preparation Example 4.

[0097] Example 7

[0098] An anti-Helicobacter pylori composition, which differs from Example 1 in that the Lactobacillus reuteri complex microcapsules were obtained from Preparation Example 5.

[0099] Example 8

[0100] An anti-Helicobacter pylori composition, which differs from Example 1 in that the Lactobacillus reuteri complex microcapsules were obtained from Preparation Example 6.

[0101] Example 9

[0102] An anti-Helicobacter pylori composition, which differs from Example 1 in that the Lactobacillus reuteri complex microcapsules were obtained from Preparation Example 7.

[0103] Example 10

[0104] An anti-Helicobacter pylori composition, which differs from Example 1 in that the Lactobacillus reuteri complex microcapsules were obtained from Preparation Example 8.

[0105] Example 11

[0106] An anti-Helicobacter pylori composition, which differs from Example 1 in that the Lactobacillus reuteri complex microcapsules were obtained from Preparation Example 9.

[0107] Example 12

[0108] An anti-Helicobacter pylori composition, which differs from Example 1 in that the Lactobacillus reuteri complex microcapsules are obtained from Preparation Example 10.

[0109] Example 13

[0110] An anti-Helicobacter pylori composition, which differs from Example 1 in that the Lactobacillus reuteri complex microcapsules are obtained from Preparation Example 11.

[0111] Example 14

[0112] An anti-Helicobacter pylori composition, which differs from Example 1 in that the Lactobacillus reuteri complex microcapsules were obtained from Preparation Example 12.

[0113] Comparative Example

[0114] Comparative Example 1

[0115] An anti-Helicobacter pylori composition, which differs from Example 1 in that the Lactobacillus reuteri complex microcapsules were obtained from Preparation Example 13.

[0116] Comparative Example 2

[0117] An anti-Helicobacter pylori composition, which differs from Example 1 in that the Lactobacillus reuteri complex microcapsules were obtained from Preparation Example 14.

[0118] Comparative Example 3

[0119] An anti-Helicobacter pylori composition, which differs from Example 1 in that the Lactobacillus reuteri complex microcapsules were obtained from Preparation Example 15.

[0120] Comparative Example 4

[0121] An anti-Helicobacter pylori composition differs from Example 1 in that it does not use Lactobacillus reuteri complex microcapsules, but instead uses Lactobacillus reuteri raw material.

[0122] Performance testing

[0123] Test samples: The anti-Helicobacter pylori compositions obtained in Examples 1-14 were selected as test samples 1-14, and the anti-Helicobacter pylori compositions obtained in Comparative Examples 1-4 were selected as control samples 1-4.

[0124] Experimental method: Thirty-six normal BALB / c mice, aged 6-8 weeks and weighing 17-20g, half male and half female, were purchased from the Animal Center of Kunming Medical University and then randomly divided into 18 groups, with one male and one female in each group.

[0125] Helicobacter pylori NCTC 11637 was inoculated onto Brucella broth medium, placed in a microaerophilic bag, and cultured at 35°C for 72 h to obtain a gavage bacterial solution. The mice were then gavaged with 200 μL of the bacterial solution each time, for a total of 3 infections, with an interval of 2 days. At this time, mild to moderate chronic active gastritis changes were observed in the gastric antrum and gastric body of the mice, indicating that the mice were infected with Helicobacter pylori.

[0126] The bacterial load was quantitatively analyzed by detecting Helicobacter pylori-specific genes (such as 16S rRNA) in the feces of Helicobacter pylori-infected mice using real-time PCR, and the resulting value was denoted as A.

[0127] Mice infected with Helicobacter pylori were treated with an anti-Helicobacter pylori composition. The mixing ratio of the anti-Helicobacter pylori composition and 35°C water was 5g:100mL. The treatment regimen was 2 mL / time × 2 times × 7 days. After the treatment, the Helicobacter pylori-specific genes (such as 16S rRNA) in the feces of the mice infected with Helicobacter pylori were detected by real-time PCR to quantitatively analyze the bacterial load. The obtained value was denoted as B.

[0128] The Helicobacter pylori eradication rate is calculated as (AB) / A. The higher the Helicobacter pylori eradication rate, the stronger the adaptability of the anti-Helicobacter pylori composition to drastic changes in the gastric acid environment, and the better the Helicobacter pylori eradication effect.

[0129] After performing the above tests on test samples 1-14 and control samples 1-4, the test results are recorded in Table 2.

[0130] Table 2 Test results of test samples 1-14 and control samples 1-4

[0131] Sample Helicobacter pylori eradication rate Test sample 1 87.5 Test sample 2 84.9 Test sample 3 85.6 Test sample 4 86.1 Test sample 5 86.8 Test sample 6 86.5 Test sample 7 86.2 Test sample 8 86.7 Test sample 9 87.1 Test sample 10 86.4 Test sample 11 86.9 Test sample 12 86.6 Test sample 13 87.0 Test sample 14 87.2 Control sample 1 77.8 Control sample 2 76.5 Control sample 3 70.4 Control sample 4 63.7

[0132] As can be seen from Example 1 and Comparative Example 4, and Table 2, this application uses calcium citrate, chitosan-citric acid complex, and mixed sol as raw materials for the microcapsule wall to encapsulate Lactobacillus reuteri raw materials into microcapsules. The resulting Lactobacillus reuteri composite microcapsules can significantly improve the Helicobacter pylori eradication rate after application, indicating that it can significantly reduce the overall impact of drastic changes in the gastric acid environment on Lactobacillus reuteri, enabling Lactobacillus reuteri to bind to Helicobacter pylori more effectively, thereby bringing about a significant Helicobacter pylori eradication effect. Combining Comparative Examples 1-3 and Table 2, it can be seen that while coating the *Lactobacillus reuteri* raw material with microcapsule walls formed from a mixed sol can improve the *Helicobacter pylori* eradication rate, this is merely a protective effect provided by the microcapsule coating structure. Further enhancement of the *Helicobacter pylori* eradication effect can be achieved by using calcium citrate or a chitosan-citric acid complex in the microcapsule walls. It was also found that the combined effect of adding calcium citrate or the chitosan-citric acid complex alone is far less than the combined effect of these two compounds acting on the microcapsule walls. Therefore, the stepwise release of *Lactobacillus reuteri* from calcium citrate and the enhanced loading effect of *Lactobacillus reuteri* and *Helicobacter pylori* from the chitosan-citric acid complex exhibit excellent synergistic effects, significantly improving the eradication of *Helicobacter pylori* in the application of this anti-*Helicobacter pylori* composition.

[0133] This specific embodiment is merely an explanation of this application and is not intended to limit it. After reading this specification, those skilled in the art can make modifications to this embodiment without contributing any inventive step, but such modifications are protected by patent law as long as they fall within the scope of the claims of this application.

Claims

1. An anti-Helicobacter pylori composition, characterized in that, It contains the following components in parts by weight: 0.5-2 parts of isomaltooligosaccharide; 1-2 parts of galactooligosaccharides; 3-5 parts sea buckthorn powder; Sorbitol 0.5-1.5 parts; L-glutamine 0.1-0.5 parts; 0.3-0.5 parts of Lactobacillus reuteri complex microcapsules; The Lactobacillus reuteri complex microcapsules were prepared through the following steps: S1. Chitosan was dissolved in citric acid solution, stirred and allowed to stand, then acetone was added to precipitate the mixture. After washing and drying, chitosan-citric acid complex was obtained. Simultaneously, sodium alginate and gelatin were mixed and dissolved in deionized water to obtain a mixed sol. S2. Take calcium citrate and mix it with the chitosan-citric acid complex and mixed sol from step S1, then add Lactobacillus reuteri raw material to disperse it, and obtain a mixed solution; S3. The mixture obtained in step S2 is added to calcium chloride solution for solidification to obtain solidified gel beads. Then, after rinsing with sterile water, it is freeze-dried to obtain Lactobacillus reuteri composite microcapsules. In step S1 of the preparation of the Lactobacillus reuteri composite microcapsules, the ratio of chitosan to citric acid solution is 1g:(60-80)mL, and the concentration of citric acid solution is 1-3%; the ratio of sodium alginate, gelatin and deionized water is (2.5-3.5)g:1g:200mL. In step S2 of the preparation of the Lactobacillus reuteri composite microcapsules, the weight ratio of calcium citrate, chitosan-citric acid complex and mixed sol is 1:(10-25):(70-90). The Lactobacillus reuteri composite microcapsules have a particle size of 150-200 μm.

2. The anti-Helicobacter pylori composition according to claim 1, characterized in that: The anti-Helicobacter pylori composition contains 1 billion to 30 billion CFU / g of Lactobacillus reuteri.

3. The anti-Helicobacter pylori composition according to claim 1, characterized in that: In step S2 of the preparation of the Lactobacillus reuteri composite microcapsules, attapulgite clay with a mass ratio of 1-5% is also added to the mixture.

4. The anti-Helicobacter pylori composition according to claim 3, characterized in that: The particle size of the attapulgite soil is 30-50 μm.

5. The method for preparing the anti-Helicobacter pylori composition according to claim 1, characterized in that: Includes the following steps: (1) Prepare raw materials containing isomaltooligosaccharide, galactooligosaccharide, sea buckthorn powder, sorbitol, L-glutamine and Lactobacillus reuteri complex microcapsules according to the formula; (2) After mixing isomaltooligosaccharide, galactooligosaccharide and sorbitol in step (1) evenly, add sea buckthorn powder and mix evenly. Finally, add Lactobacillus reuteri complex microcapsules and L-glutamine and mix evenly. Then, package and store to obtain the anti-Helicobacter pylori composition.